Online registration

Registration for

Alentis Therapeutics: novel mechanisms to treat advanced liver diseases

18. February 2020, 18:30 to 20:00

Markthalle Basel, "Salon", Steinentorberg 20, 4052 Basel

unfortunately are no longer possible.


Unfortunately, the registration for this event is closed. in conjunction with our partner KPMG are proud to invite you to this event featuring Alentis Therapeutics, which is a Basel-based company built on groundbreaking research from its founder Prof. Thomas Baumert, MD, Professor of Medicine and institute head at the University of Strasbourg. The company seeded by BaseLaunch raised in 2019 a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures.

Alentis develops first in class drugs that address the growing unmet need in advanced liver diseases such as fatty liver, fibrosis, cirrhosis and liver cancer, now the second leading cause of cancer death world-wide. Changes in life style including obesity are a major driver for the increasing impact of liver disease.  Advanced fibrosis is either held steady or gets progressively worse, raising the risk of patients developing liver cancer. Alentis believes it doesn’t have to be that way based on their approach to develop compounds with novel mechanisms of action.

The company explores its proprietary discovery platform that enables identification of novel targets and biomarkers as well as revealing new drug candidates. Its lead compound leverages a previously unknown MoA for fibrosis by targeting a liver cell surface protein which plays are key role in liver disease.

This event will have Dr. Thomas Baumert talking about the story of the company, their plans for the future and their approach to developing therapeutics for liver diseases, as well as a brief introduction on the liver disease space from KPMG.